Acute phase intra-stent tissue reduction effect of prasugrel compared with clopidogrel in patient with acute coronary syndrome

Acute phase intra-stent tissue reduction effect of prasugrel compared with clopidogrel in patient with acute coronary syndrome - Acute effect of parsugrel in ACS

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000018751

Enrollment

100

Registered

2015-08-21

Start date

2015-09-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute coronary syndrome

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)The patient with ACS undergoing primary PCI to curprit lesion with stent implantation. 2)The patient scheduled to be performed secondary OCT after 3days to 1month of primary PCI.

Exclusion criteria

Exclusion criteria: 1. Patients who cannot give informed consent. 2. Absolute contraindications or allergy that cannot be pre-medicated to iodinated contrast or to any of the study medications including both prasgrel and clopidgrel. 3. Contraindications to angiography. 4. If it is known, pregnant or nursing mothers. 5. If it is known, a creatinine clearance <30 mL/min. 6. Previous enrolment in this study. 7. Randomisation or planned use of other investigational drugs or devices in this trial. 8. the opinion of the investigator would result in suboptimal imaging or excessive risk of complication from placement of an OCT catheter. 9. insufficient OCT image quality 10. stent thrombosis was developed before secondary OCT 11. cardiac arrest 12. PCI performed on the next day after PCI due to unstable hemodynamic status or chest pain 13. Curprit lesion located in (left main trunk or in )the ostial coronary artery or in a previous stent implantation(stent occulusion or stent restenosis) or in a saphenous vein graft ,in arterial bypass. 14. Stroke was developed after PCI 15. uncontrollable heart failure 16. active bleeding 17. active infection

Design outcomes

Primary

Measure	Time frame
The primary end point of the study was IST score reduction between the 2 treatment groups.	—

Secondary

Measure	Time frame
The secondary end points was the difference in each maximal smooth and irregular IST area reduction between the 2 treatment groups.	—

Countries

Japan

Contacts

Public ContactYoshiro Tsukiyama

Kobe University Graduate School of Medicine Division of Cardiology

yoshiro.tsukiyama0920@gmail.com078-382-5111

Outcome results